US3048526A - Medicinal tablet - Google Patents

Medicinal tablet Download PDF

Info

Publication number
US3048526A
US3048526A US752768A US75276858A US3048526A US 3048526 A US3048526 A US 3048526A US 752768 A US752768 A US 752768A US 75276858 A US75276858 A US 75276858A US 3048526 A US3048526 A US 3048526A
Authority
US
United States
Prior art keywords
tablet
compressed
inlay
main body
inlay portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US752768A
Inventor
Charles L Boswell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wander Co
Original Assignee
Wander Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wander Co filed Critical Wander Co
Priority to US752768A priority Critical patent/US3048526A/en
Priority claimed from GB22359A external-priority patent/GB888038A/en
Application granted granted Critical
Publication of US3048526A publication Critical patent/US3048526A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/22—Nonparticulate element embedded or inlaid in substrate and visible
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/24—Structurally defined web or sheet [e.g., overall dimension, etc.]
    • Y10T428/24479—Structurally defined web or sheet [e.g., overall dimension, etc.] including variation in thickness
    • Y10T428/24521—Structurally defined web or sheet [e.g., overall dimension, etc.] including variation in thickness with component conforming to contour of nonplanar surface

Definitions

  • This invention relates to a novel and improved me dicinal tablet and more particularly to a tablet of the type containing substantially segregated quantities of the same or different ingredients.
  • each dosage unit contains segregated quantities of the ingredients of the preparation.
  • one type ot' medicinal tablet or pill which is useful for delayed action or multiple dosage medication is the so-called tablet-wi-thin-a-tablet or double tablet Construction which consists of an innermost core tablet, a thin enteric coating around the core tablet, and an outermost shell or layer.
  • the medicinal ingredients in the outermost shell are readily assimilated in the gastro-intestinal tract to pro-vide immediate therapy.
  • the gastrointestinal fluids dissolve the enteric coatin on the inner core portion of the tablet and the ingredients of the latter are. then available for assimilation.
  • layered tablet which consists of two or more superimposed layers of medicinal ingredients compressed together to form a unitary tablet.
  • a layered or multiple compressed tablet of this type is used primarily in sit-uations where it is necessary to separate or segregate two different pharmaceutical ingredients which are to be administered at the same time but which have an adverse effect upon each other so that they cannot be intimately commingled beforehand.
  • an acidic medicinal ingredient may have a detrimental ettect on a companion ingredient which is susceptible to acid action.
  • both the tablet-within-a tablet and the layered tablet constructions have serious limitations.
  • the inherent geometry of the Construction is such that the quantity of mea that the tablet-within-a-tablet Construction avoids this dicinal ingredient or ingredients forming the outer shell of the tablet is always substantially greater than the quantity of material forming the inner core of the table-t.
  • the dosage content in the outer shell may be as much as twice as great as the dosage content of the inner core tablet.
  • the tablet-withina-tablet Construction it is necessarily the outer shell portion of the tablet which is first released and assimilated in the gastrointestinal traot. It will readily be understood that these limitations may frequently restrict the scope and utility of this tablet form.
  • the chief disadvantages are an undesirable merging of the ingredients at the interface between the layers and also a poor degree of control over the relative quantities of the ingredients in the respective layers.
  • These disadvantages are occasioned by the necessity of producing a layered tablet in a single compression step so as to o btain a unitary tablet having the required mechanical strength and coherence.
  • the layered tablet is formed 'by successively introducng into a die cavity measured amounts of the respective granulated ingredients so as to form two or more superirnposed layers of the several ingredients.
  • a plunger compresses latter difliculty because the inner core 'portion is preformed in a first tabletting or compression operation and thereafter the outer shell is compressed around the preformed core so that there is 'no merging under pressure of the separate granulations.
  • a primary object of the invention is to provide a novel and improved form of medicinal tablet of the type adapted to contain substantially segregated quantities of ingredients.
  • a further object of the invention is to provide a novel and improved medicinal tablet of the aforementioned type which combines the advantages of the prior ⁇ art tablet forms without the disadvantages thereof.
  • Another object of the invention is to provide a novel and improved medicinal tablet which is particularly adapted to contain incompatible ingredents which must be protected from each other.
  • FIG. l is a plan view of a tablet comprising one specific embodiment of the present invention.
  • FIG. 2 is an edge view 'of the tablet shown in FIG. 1;
  • FIG. 3 is a transverse sectional view as seen along the line 3--3 of FIG. 1;
  • FIG. 4 is a view similar to FIG. 3 but showing a modilied form of the invention
  • FIG. 5 is a sectional view similar to FIG.. 3 but showing another embodiment of the invention.
  • EIG. 6 is a sectional View of still another emb odiment of the invention
  • a tablet 10 is shown of a conventional overall configuration and having a main body portion 11 with an outwardly opening cavity or recess i?. in one side thereof and an inlay portion 13 contained in the ⁇ cavity 12 so as to form a unitary tablet construction with the main body portion 11.
  • a modification is shown in FIG. 5 wherein the main body portion 11' extends radially inwardly to a slight extent around the marginal edge of the opening of the cavity 12 in the side of the tablet so as to provide ⁇ an overlying peripheral lip portion 14- for retaining and mechanically interlocking with the inlay tablet portion 13.
  • the inlay portion 13 is first compressed in a tabletting machine in the usual manner to provide a compressed preform. This preform is then subjected to a further tabletting operation of a conventional character wherein another granulation is compressed around the preform 13 to provide the surrounding body portion lili.
  • both the inlay portion 13 and the main body portion 11 of the tablet are formed by independent compression or tabletting steps, it will be understood that highly accurate control can be exercised over the quantities of ingredients which form the two parts of the tablet. Furtherrnore, since both the inlay portion 13 and the main body portion 11 have exposed outer surfaces, it can readily be arranged to permit either the portion il or the portion 13 to be released first in the gastrointestinal tract with any desired degree of time delay in the release or assirnilaton of the other portion of the tablet. in the present emhodiment as seen in FIG.
  • dilferential releasability between the portions 11 and 13 of the tablet is realized by using a coated granulation for one portion and an uncoated granulation for the other portion of the tablet.
  • the portion 13 may be preformed from an uncoated granulation so that this portion is immediately dissolved in the gastrointestinal tract.
  • the main body portion 11 of the tablet comprising a larger dosage of the same ingredients may be formulated as coated granulation in which each granular particle has a time delay or enteric coating designed to resist assimilation in the gastrointestinal fluids.
  • Such coated granulations are well known in the art and require no detailed description.
  • the same technique of coated and uncoated granulations for the inlay and main body portions of the tablet may be utilized where the tablet portions contain different medicinal ingredients which have an adverse effect on each other and must, therefore, be protected from each other.
  • the larger portion 11 may be formed from an uncoated granulation so as to be assimilated first and the smaller inlay portion 13 may be formed from a coated granulation for delayed assimilation thereof.
  • FIG. 4 a modification of the invention is shown wherein segregaton of the inlay and main body portions of the tablet, for purposes of time delay or positive separation of incompatible ingredients, is realized without the necessity of employing ⁇ a coated granulation for one of the tablet portions.
  • the preformed inlay portion of the tablet, designated at 16 may be formulated from an uncoated granulatior and is then surrounded by a thin enteric coating or envelope 17 of a conventional character.
  • the main body portion is desgnated at 18 and may also consist of an uncoated granulation which is conipressed around the enteric coated inlay portion lid-17.
  • the main body portion 18 of the tablet is first released and assimilated in the gastrointestinal tract while the enteric coating 17 protects the inlay portion 16 for a predetermined period of time so as to provide time delayed or sustained medication.
  • the particles of the granulation in either or both portions of the tablet may be coated to any desired degree so 'as to provide a further degree of control over the time release feature and positive segregation feature of the tablet construction.
  • enteric coating materials are well known to those skilled in the art and extended discussion thereof is, therefore, unnecessary.
  • enterc coating materials include cellulose acetate phthalate, tolu balsam, carnauba wax, alcoholic shellac solutions, hydrogenated fats, etc. It will he understood that the same general types of enteric coating materials may be used for coating either an entire compressed tablet portion or the individual particles of a granulation prior to compression.
  • a further modification of the invention comprisng a tablet having a main body portion and two separate inlay portions at opposite sides of the tablet.
  • the two oppositely disposed inlay portions are designated at 19 and Zi wit i the main body portion being designated at 22.
  • the inlay portons 19' and 21 have exposed surfaces at opposite sides of the tablet and that the material comprising the main body portion 22. extends around the peripheral edges of the inlay portions and is also disposed as a thin layer between the inlay portons so that the latter are completely segregated from' each other.
  • the previously discussed advantages of the invention are extended even further by means of the double inlay arrangement.
  • the inlay portions 19 and 21 may conprise the same or dierent pharmaceutical compositions and they may be ⁇ coated or uncoated so as to provide any desired sequence of delayed or concurrent release between the respective portions 19, Zi, and'ZZ of the tablet in accordance with the means heretofore described.
  • Example I An appetite depressant tablet is formulated in the manner shown in FIGS. 1-3.
  • the particles of the granulation are enteric coated to provide slow release over a period of ten to twelve hours.
  • the inlay portion is formed from an uncoated readily disintegratable granulation for immediate therapeutic eifectiveness.
  • Example H An oral decongestant tablet is formulated as in Example I with the outer layer comprising a coated granulatior and the inlay portion an uncoated granulation.
  • the formula for the outer layer is as follows:
  • the outer layer is promptly disintegratable for immediate hypnotic effect and the inlay portion begins to disintegrate after three to four hours to maintain or continue the desired effect.
  • the invention provides a novel tablet Construction which provides wide flexibility in the compositing of segregated quantities of medicinal ingredients either for purposes of time delayed medication or protection of inconpatible ingredients from each other.
  • the tablet form permits of positive separation of the segregated areas with accurate control over the relative amounts of the several portions of the tablet.
  • the -final tablet is readily adapted for varying relative dosages of difierent ingredients and varying orders of releasability depending upon the therapeutic effects desired.
  • conventional tabletting and compression coating machines will require only relatively minor modifications to adapt them to the production of inlay tablets as herein described, particularly with respect to FIGS. 1-4.
  • the inlay construction of the tablet aiords a unique and distinctive appearance, particularly if the inlay portion of the tablet is of a eontrasting color with respect to the surrounding body portion thereby contributing significant advantages to the tablet constructon both during production and merchandising.
  • the presence of an exposed inlay portion of contrasting color with the remainder of the tablet provides instant visual proof that a complete tablet has been made and thereby greatly facilitates inspection of the final product before ackaging and shippng.
  • a method of making an oral dosage tablet form which comprises; compressing a finely divided medicinal ingredient portion to form a compressed tablet inlay portion having smaller dimensions than the desired finished tablet form, positioning the preformed compressed tablet inlay portion in contact with a second finely divided medicinal ingredient portion, compressing said second medicinal ingredient portion about only a part of said compressed tablet inlay portion to form a compressed main body portion and exposing only a single surface of said compressed tablet inlay portion on the outer surface of the finished tablet form, and said single surface lying in substantially a common plane with contiguous portions of said compressed main body portion.
  • An oral dosage tablet form comprising; a compressed tablet inlay portion of a finely divided medicinal ingredient portion with said compressed tablet inlay portion having smaller dimensions :than the desired finished tablet, and a compressed main body portion comprising a second medicinal ingredient portion compressed about only a part of said tablet inlay portion with only a single surface of said compressed tablet inlay portion exposed on the outer surface of the finished tablet form and said single surface lying substantially in a common plane with contiguous portions of said compressed main body portion, and said oral dosage tablet form being made by compressing the first mentioned said finely divided medicinal ingredient portion to form said compressed tablet inlay portion, positioning said compressed tablet inlay portion in contact with said second finely divided medicinal ingredient portion, compressing said second medicinal ingredient portion about only a part of said compressed tablet inlay portion to form said compressed main body portion and expose only said single surface of said compressed tablet inlay portion on the outer surface of the finished tablet form with said single surface lying in substantially a common plane with contiguous portions of said main body portion.
  • a method of treating a human body with a drug which comprises; administerng to a human host an oral dosage tablet form comprising a compressed tablet inlay portion of a finely divided medicinal ingredient portion with said compressed tablet inlay portion having smaller dimensions than the desired finished tablet form, and a compressed main body portion comprising a second medicinal ingredient portion compressed about only a part of said compressed tablet inlay portion With a single surface of said tablet inlay portion exposed on the outer surface of said finished tablet form, and said single surface lying substantially in a common plane with contiguous portions of said main body portion.

Description

1962 c. L. BOSWELL 3,048,526
MEDICINAL TABLET Filed Aug. 4, 1958 /l//ll//l//l//l/l/ 22 I z OT 5 NV.
!e e& 14 13 12 3,048 526 Fatented Aug. 7, 1962 &948,526 MEDECINAL TABLET Charles L. Bosweil, Lincoln, Nebr., assignor to The Wander Company, Chicago, ill., a corporation of Deiaware Filed Ang. 4, 1953, Ser. No. '752,768 4 Ciaims. (Cl. 167--82) This invention relates to a novel and improved me dicinal tablet and more particularly to a tablet of the type containing substantially segregated quantities of the same or different ingredients.
lt is frequently desired to provide medicinal or pharmaceutical compositions in solid dosage unit form wherein each dosage unit contains segregated quantities of the ingredients of the preparation. For example, one type ot' medicinal tablet or pill which is useful for delayed action or multiple dosage medication is the so-called tablet-wi-thin-a-tablet or double tablet Construction which consists of an innermost core tablet, a thin enteric coating around the core tablet, and an outermost shell or layer. Upon oral administration, the medicinal ingredients in the outermost shell are readily assimilated in the gastro-intestinal tract to pro-vide immediate therapy. After a predetermined period of time, the gastrointestinal fluids dissolve the enteric coatin on the inner core portion of the tablet and the ingredients of the latter are. then available for assimilation. Thus, 'a sustained or delayed action eifect is realized which is equivalent to the result which would be obtained by repeated administration of conventional tablets over a period of time. Another type of medicinal tab-let which is also employed in certain instances is the so-called layered tablet which consists of two or more superimposed layers of medicinal ingredients compressed together to form a unitary tablet. A layered or multiple compressed tablet of this type is used primarily in sit-uations where it is necessary to separate or segregate two different pharmaceutical ingredients which are to be administered at the same time but which have an adverse effect upon each other so that they cannot be intimately commingled beforehand. For example, an acidic medicinal ingredient may have a detrimental ettect on a companion ingredient which is susceptible to acid action.
However, both the tablet-within-a tablet and the layered tablet constructions have serious limitations. For example, in the tablet-within-a-tablet the inherent geometry of the Construction is such that the quantity of mea that the tablet-within-a-tablet Construction avoids this dicinal ingredient or ingredients forming the outer shell of the tablet is always substantially greater than the quantity of material forming the inner core of the table-t. In a typical instance, the dosage content in the outer shell may be as much as twice as great as the dosage content of the inner core tablet. Moreover, in the tablet-withina-tablet Construction it is necessarily the outer shell portion of the tablet which is first released and assimilated in the gastrointestinal traot. It will readily be understood that these limitations may frequently restrict the scope and utility of this tablet form.
In the layered tablet, the chief disadvantages are an undesirable merging of the ingredients at the interface between the layers and also a poor degree of control over the relative quantities of the ingredients in the respective layers. These disadvantages are occasioned by the necessity of producing a layered tablet in a single compression step so as to o btain a unitary tablet having the required mechanical strength and coherence. Generally speaking, the layered tablet is formed 'by successively introducng into a die cavity measured amounts of the respective granulated ingredients so as to form two or more superirnposed layers of the several ingredients. After the die cavity is filled, a plunger compresses latter difliculty because the inner core 'portion is preformed in a first tabletting or compression operation and thereafter the outer shell is compressed around the preformed core so that there is 'no merging under pressure of the separate granulations.
In View of the foregoing discussion, it will be seen that there is a decided need for an improved tablet form which afiords the advantages of both the tablet-within-atablet and the layered tablet constructions without the disadvantages inherent in each of these known therapeutic forms.
Accor-dingly, a primary object of the invention is to provide a novel and improved form of medicinal tablet of the type adapted to contain substantially segregated quantities of ingredients.
A further object of the invention is to provide a novel and improved medicinal tablet of the aforementioned type which combines the advantages of the prior `art tablet forms without the disadvantages thereof.
Another object of the invention is to provide a novel and improved medicinal tablet which is particularly adapted to contain incompatible ingredents which must be protected from each other.
' for production on modern high speed taljletting equipment.
Other objects and advantages of the invention will become apparent from the subsequent detailed description taken in conjunction with the accompanying drawing, wherein:
FIG. l is a plan view of a tablet comprising one specific embodiment of the present invention;
FIG. 2 is an edge view 'of the tablet shown in FIG. 1;
FIG. 3 is a transverse sectional view as seen along the line 3--3 of FIG. 1;
FIG. 4 is a view similar to FIG. 3 but showing a modilied form of the invention;
FIG. 5 is a sectional view similar to FIG.. 3 but showing another embodiment of the invention; and
EIG. 6 is a sectional View of still another emb odiment of the invention Referring first to FIGS. 1 to 3 and 5, a tablet 10 is shown of a conventional overall configuration and having a main body portion 11 with an outwardly opening cavity or recess i?. in one side thereof and an inlay portion 13 contained in the `cavity 12 so as to form a unitary tablet construction with the main body portion 11. A modification is shown in FIG. 5 wherein the main body portion 11' extends radially inwardly to a slight extent around the marginal edge of the opening of the cavity 12 in the side of the tablet so as to provide `an overlying peripheral lip portion 14- for retaining and mechanically interlocking with the inlay tablet portion 13. In manufacturing the tablet, the inlay portion 13 is first compressed in a tabletting machine in the usual manner to provide a compressed preform. This preform is then subjected to a further tabletting operation of a conventional character wherein another granulation is compressed around the preform 13 to provide the surrounding body portion lili.
Inasmuch as both the inlay portion 13 and the main body portion 11 of the tablet are formed by independent compression or tabletting steps, it will be understood that highly accurate control can be exercised over the quantities of ingredients which form the two parts of the tablet. Furtherrnore, since both the inlay portion 13 and the main body portion 11 have exposed outer surfaces, it can readily be arranged to permit either the portion il or the portion 13 to be released first in the gastrointestinal tract with any desired degree of time delay in the release or assirnilaton of the other portion of the tablet. in the present emhodiment as seen in FIG. 3, dilferential releasability between the portions 11 and 13 of the tablet is realized by using a coated granulation for one portion and an uncoated granulation for the other portion of the tablet. For example, assuming that the inlay portion 13 comprisng the smaller dosage of ingredients is to be assrnilated first, the portion 13 may be preformed from an uncoated granulation so that this portion is immediately dissolved in the gastrointestinal tract. However, the main body portion 11 of the tablet comprising a larger dosage of the same ingredients may be formulated as coated granulation in which each granular particle has a time delay or enteric coating designed to resist assimilation in the gastrointestinal fluids. Such coated granulations are well known in the art and require no detailed description. It will also be understood that the same technique of coated and uncoated granulations for the inlay and main body portions of the tablet may be utilized where the tablet portions contain different medicinal ingredients which have an adverse effect on each other and must, therefore, be protected from each other. Also, it will be appreciated that the larger portion 11 may be formed from an uncoated granulation so as to be assimilated first and the smaller inlay portion 13 may be formed from a coated granulation for delayed assimilation thereof.
In FIG. 4, a modification of the invention is shown wherein segregaton of the inlay and main body portions of the tablet, for purposes of time delay or positive separation of incompatible ingredients, is realized without the necessity of employing `a coated granulation for one of the tablet portions. Thus, the preformed inlay portion of the tablet, designated at 16, may be formulated from an uncoated granulatior and is then surrounded by a thin enteric coating or envelope 17 of a conventional character. The main body portion is desgnated at 18 and may also consist of an uncoated granulation which is conipressed around the enteric coated inlay portion lid-17. In this modification of the invention the main body portion 18 of the tablet is first released and assimilated in the gastrointestinal tract while the enteric coating 17 protects the inlay portion 16 for a predetermined period of time so as to provide time delayed or sustained medication.
Of course, in addition to the provision of a separate enteric coating or envelope for the inlay portion of the tablet as illustrated in FIG. 4, the particles of the granulation in either or both portions of the tablet may be coated to any desired degree so 'as to provide a further degree of control over the time release feature and positive segregation feature of the tablet construction.
Various enteric coating materials are well known to those skilled in the art and extended discussion thereof is, therefore, unnecessary. :For example, the more common enterc coating materials include cellulose acetate phthalate, tolu balsam, carnauba wax, alcoholic shellac solutions, hydrogenated fats, etc. It will he understood that the same general types of enteric coating materials may be used for coating either an entire compressed tablet portion or the individual particles of a granulation prior to compression.
In FG. 6, a further modification of the invention is shown comprisng a tablet having a main body portion and two separate inlay portions at opposite sides of the tablet. Thus, the two oppositely disposed inlay portions are designated at 19 and Zi wit i the main body portion being designated at 22. It will be noted that the inlay portons 19' and 21 have exposed surfaces at opposite sides of the tablet and that the material comprising the main body portion 22. extends around the peripheral edges of the inlay portions and is also disposed as a thin layer between the inlay portons so that the latter are completely segregated from' each other. As will readily be understood, the previously discussed advantages of the invention are extended even further by means of the double inlay arrangement. For example, the inlay portions 19 and 21 may conprise the same or dierent pharmaceutical compositions and they may be `coated or uncoated so as to provide any desired sequence of delayed or concurrent release between the respective portions 19, Zi, and'ZZ of the tablet in accordance with the means heretofore described.
Merely by way of illustration, the following specific examples represent typical inlay tablets which may be made in accordance with the present invention.
Example I An appetite depressant tablet is formulated in the manner shown in FIGS. 1-3. In the outer layer the particles of the granulation are enteric coated to provide slow release over a period of ten to twelve hours. The inlay portion is formed from an uncoated readily disintegratable granulation for immediate therapeutic eifectiveness.
The formula for the outer layer is as fcllows:
d-Amphetamine sulfate mg 10 Amobarbital rng 30 Excipients q.s. Enteric coating solution for coatng granulation q.s.
The formula for the inlay portion is as follows:
d-Amphetamine sulfate "mg" 5 Amobarbital mg 15 Excipients q.s. Standard granulating solution q.s.
Example H An oral decongestant tablet is formulated as in Example I with the outer layer comprising a coated granulatior and the inlay portion an uncoated granulation.
The formula for the outer layer is as follows:
with an enteric coating or envelope around the inlay portion. Thus, the outer layer is promptly disintegratable for immediate hypnotic efect and the inlay portion begins to disintegrate after three to four hours to maintain or continue the desired effect.
Pharmaceutical glaze shellac granulating solution q.s. Enteric eoating materials for coating inlay portion of tablet q.s.
Although in the illustrated embodiments the invention has been described in connection with tablets having the conventional round shape, it is to be understood that the features of the invention may also be utilized in tablets of different and less conventional shape such as triangular, rectangular, or capsule shaped tablets.
As described above, it will be seen that the invention provides a novel tablet Construction which provides wide flexibility in the compositing of segregated quantities of medicinal ingredients either for purposes of time delayed medication or protection of inconpatible ingredients from each other. At the same time, the tablet form permits of positive separation of the segregated areas with accurate control over the relative amounts of the several portions of the tablet. The -final tablet is readily adapted for varying relative dosages of difierent ingredients and varying orders of releasability depending upon the therapeutic effects desired. Moreover, in most cases conventional tabletting and compression coating machines will require only relatively minor modifications to adapt them to the production of inlay tablets as herein described, particularly with respect to FIGS. 1-4. Finally, the inlay construction of the tablet aiords a unique and distinctive appearance, particularly if the inlay portion of the tablet is of a eontrasting color with respect to the surrounding body portion thereby contributing significant advantages to the tablet constructon both during production and merchandising. For example, during production the presence of an exposed inlay portion of contrasting color with the remainder of the tablet provides instant visual proof that a complete tablet has been made and thereby greatly facilitates inspection of the final product before ackaging and shippng.
Although the invention has been illustrated and described with respect to certain specific embodiments thereof, it is to be understood that various modifications and alternatives may be resorted to without depart'ng from the scope of the invention as defined in the appended claims. r
I claim:
1. A method of making an oral dosage tablet form which comprises; compressing a finely divided medicinal ingredient portion to form a compressed tablet inlay portion having smaller dimensions than the desired finished tablet form, positioning the preformed compressed tablet inlay portion in contact with a second finely divided medicinal ingredient portion, compressing said second medicinal ingredient portion about only a part of said compressed tablet inlay portion to form a compressed main body portion and exposing only a single surface of said compressed tablet inlay portion on the outer surface of the finished tablet form, and said single surface lying in substantially a common plane with contiguous portions of said compressed main body portion.
2. An oral dosage tablet form comprising; a compressed tablet inlay portion of a finely divided medicinal ingredient portion with said compressed tablet inlay portion having smaller dimensions :than the desired finished tablet, and a compressed main body portion comprising a second medicinal ingredient portion compressed about only a part of said tablet inlay portion with only a single surface of said compressed tablet inlay portion exposed on the outer surface of the finished tablet form and said single surface lying substantially in a common plane with contiguous portions of said compressed main body portion, and said oral dosage tablet form being made by compressing the first mentioned said finely divided medicinal ingredient portion to form said compressed tablet inlay portion, positioning said compressed tablet inlay portion in contact with said second finely divided medicinal ingredient portion, compressing said second medicinal ingredient portion about only a part of said compressed tablet inlay portion to form said compressed main body portion and expose only said single surface of said compressed tablet inlay portion on the outer surface of the finished tablet form with said single surface lying in substantially a common plane with contiguous portions of said main body portion.
3. An oral dosage tablet form as defined in claim 2, wherein said finished tablet form has a second compressed tablet inlay portion disposed therein with said second compressed tablet inlay portion having only a single surface thereof'exposed on the outer surface of said finished tablet form.
4. A method of treating a human body with a drug which comprises; administerng to a human host an oral dosage tablet form comprising a compressed tablet inlay portion of a finely divided medicinal ingredient portion with said compressed tablet inlay portion having smaller dimensions than the desired finished tablet form, and a compressed main body portion comprising a second medicinal ingredient portion compressed about only a part of said compressed tablet inlay portion With a single surface of said tablet inlay portion exposed on the outer surface of said finished tablet form, and said single surface lying substantially in a common plane with contiguous portions of said main body portion.
References Cited in the file of this patent UNITED STATES PATENTS 109,677 Seitz Nov. 29, 1870 701,438 Whyte June 3, 1902 1,267,320 Fries May 21, 1918 `1,5 16,398 McDowell Nov. 3, 1924 1,855,- Jones Apr. 19, 1932 2,312,381 Bi'ckenheuser Mar. 2, 1943 '2,809,917 Hermelin Oct. 15, 1957 2,951,792 Swintosky Sept. 6, 1960 2,957,804 Shuyler Oct. 25, 1960 2,987,445 Levesque June 6, 1961 2,991,226 Millar et a-l. July 4, 1961 2,966,431 Barry Aug; 15, 1961 FOREIGN PATENTS 1,651 Great Britain 1891 OTHER REFERENCES Drug and Cosmetic Industry, vol. 7 8, No. 1, article Press-Coated and Multi-Layer Tablets, by Tsevdos, January 1956, pages 38, 39, 40, 113 114.

Claims (1)

  1. 2. AN ORAL DOSAGE TABLET FORM COMPRISING; A COMPRESSED TABLET INLAY PORTION OF A FINELY DIVIDED MEDICINAL INGREDIENT PORTION WITH SAID COMPRESSED TABLET INLAY PORTION HAVING SMALLER DIMENSIONS THAN THE DESIRED FINISHED TABLET, AND A COMPRESSED MAINBODY PORTION COMPRISING A SECOND MEDICINAL INGREDIENT PORTION COMPRESSED ABOUT ONLY A PART OF SAID TABLET INLAY PORTION WITH ONLY A SINGLE OF SAID COMPRESSED TABLET INLAY PORTION EXPOSED ON THE OUTER SURFACE OF THE FINISHED TABLET FORM AND SAID SINGLE SURFACE LYING SUBSTANTIALLY IN A COMMON PLANE WITH CONTIGUOUS PORTIONS OF SAID COMPRESSED MAIN BODY BODY PORTION, AND SAID ORAL DOSAGE TABLET FORM BEING MADE BY COMPRESSING THE FIRST MEMTIONED SAID FINELY DIVIDED MEDICINAL INGREDIENT PORTION TO FORM SAID COMPRESSED TABLET INLAY PORTION, POSITIONING SAID COMPRESSED TABLET INLAY PORTION IN CONTACT WITH SAID SECOND MEDICINAL INGREDIENT PORTION, COMPRESSING SAID SECOND MEDICINAL INGREDIENT PORTION ABOUT ONLY A PART OF SAID COMPRESSED TABLET INLAY PORTION TO FORM SAID COMPRESSED MAIN BODY PORTION AND EXPOSE ONLY SAID SINGLE SURFACE OF SAID COMPRESSED TABLET INLAY PORTION ON THE OUTER SURFACE OF THE FINISHED TABLET FORM WITH SAID SINGLE SURFACE LYING IN SUBSTANTIALLY A COMMON PLANE WITH CONTIGUOUS PORTIONS OF SAID MAIN BODY PORTION.
US752768A 1958-08-04 1958-08-04 Medicinal tablet Expired - Lifetime US3048526A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US752768A US3048526A (en) 1958-08-04 1958-08-04 Medicinal tablet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US752768A US3048526A (en) 1958-08-04 1958-08-04 Medicinal tablet
GB22359A GB888038A (en) 1959-12-16 1959-12-16 Medicinal tablet

Publications (1)

Publication Number Publication Date
US3048526A true US3048526A (en) 1962-08-07

Family

ID=26235774

Family Applications (1)

Application Number Title Priority Date Filing Date
US752768A Expired - Lifetime US3048526A (en) 1958-08-04 1958-08-04 Medicinal tablet

Country Status (1)

Country Link
US (1) US3048526A (en)

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3121044A (en) * 1960-10-06 1964-02-11 Beecham Res Lab Three-layer compressed penicillin tablet
US3125490A (en) * 1964-03-17 Tablet with contrasting indicia and method
US3125491A (en) * 1962-04-06 1964-03-17 Chew able hematinic vitamin tablet
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
FR2073278A1 (en) * 1969-12-17 1971-10-01 Sogeras Two-component tablets - having a distinctive pattern on one side
US3922338A (en) * 1973-07-12 1975-11-25 Choay Sa Tablets containing in their mass controlled-release micro-capsules and process for manufacture of said tablets
US4139589A (en) * 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4198390A (en) * 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
US4454108A (en) * 1981-09-04 1984-06-12 Chugai Seiyaku Kabushiki Kaisha Prolonged-action multiple-layer tablets
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
AU632602B2 (en) * 1989-08-02 1993-01-07 John David Arnold Method and preparation for reducing risk of myocardial infarction
US5213807A (en) * 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5599577A (en) * 1992-05-21 1997-02-04 Mcneil-Ppc, Inc. Simethicone containing pharmaceutical compositions
US5759574A (en) * 1995-05-15 1998-06-02 Bothe; Steven T. Tel-tale-tablets
US5817340A (en) * 1992-12-01 1998-10-06 Mcneil-Ppc, Inc. Pharmaceutical compositions containing famotidine and aluminum hydroxide or magnesium hydroxide
US5849330A (en) * 1991-09-17 1998-12-15 Orion-Yhtyma Oy Controlled release pharmaceutical
USD420464S (en) * 1998-03-20 2000-02-08 Colgate-Palmolive Co. Detergent tablet
USD430345S (en) * 1999-09-24 2000-08-29 Van Der Hagen John Two part circular soap article
US6428770B1 (en) * 1997-12-03 2002-08-06 Kao Corporation Solid preparation for oral hygiene
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US20040096499A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel dosage form
US20040180089A1 (en) * 2002-12-26 2004-09-16 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US20040219213A1 (en) * 1998-10-21 2004-11-04 Burnside Beth A. Oral pulsed dose drug delivery system
WO2004093850A1 (en) 2003-04-24 2004-11-04 Jagotec Ag Tablet with coloured core
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
US20060057201A1 (en) * 2002-07-25 2006-03-16 Bonney Stanley G Multicomponent pharmaceutical dosage form
US20060193909A1 (en) * 2005-02-07 2006-08-31 Stawski Barbara Z Breath freshening pressed tablets and methods of making and using same
US20070054014A1 (en) * 2005-02-07 2007-03-08 Stawski Barbara Z Breath freshening confectionery products and methods of making and using same
WO2007043061A1 (en) * 2005-10-11 2007-04-19 Ipca Laboratories Ltd. Anti-malarial combination and methods of formulation
US20070166430A1 (en) * 2004-04-20 2007-07-19 Stawski Barbara Z Breath freshening confectionery products and methods of making and using same
US20070166380A1 (en) * 2005-11-18 2007-07-19 Frans Van Dalen Zolpidem tablets
US20070264323A1 (en) * 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system
US20080020047A1 (en) * 2006-07-24 2008-01-24 Alexander Thomas A Method for distributing a pharmaceutically active compound in an excipient
US20090062336A1 (en) * 2004-04-26 2009-03-05 Celgene Corporation Methods of Diminishing Co-Abuse Potential
US20090087483A1 (en) * 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US20090088455A1 (en) * 1995-12-04 2009-04-02 Celgene Corporation Chronic, Bolus Adminstration Of D-Threo Methylphenidate
US20090090361A1 (en) * 2007-10-09 2009-04-09 Anand Gumaste Inhalation device
US20090110721A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Paneled capsule shells for release of pharmaceutical compositions
US20090110723A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms
US20090108492A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Method and apparatus for manufacturing filled linkers
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
US20100143469A1 (en) * 2006-10-09 2010-06-10 Paul Bosse Pharmaceutical compositions
US20100196427A1 (en) * 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
KR101013272B1 (en) * 1998-12-04 2011-02-08 사노피-아벤티스 Controlled-release dosage forms comprising zolpidem or a salt thereof
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
USD666376S1 (en) * 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
USD666377S1 (en) * 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
USD677438S1 (en) * 2011-12-13 2013-03-05 Sunbeam Products, Inc. Bark control device housing
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US20130295174A1 (en) * 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Tablet comprising a first and second region
USD697510S1 (en) * 2011-03-23 2014-01-14 Brother Industries, Ltd. Scanner with projector
US8709491B2 (en) 2011-06-28 2014-04-29 NEOS Terapeutics, LP Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
US8728522B2 (en) 2009-07-08 2014-05-20 Charleston Laboratories, Inc. Pharmaceutical compositions for treating or preventing pain
US8747902B2 (en) 2006-03-16 2014-06-10 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
USD714787S1 (en) * 2013-09-12 2014-10-07 Hiku Labs, Inc. Handheld device
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US8991390B2 (en) 2010-01-05 2015-03-31 Microdose Therapeutx, Inc. Inhalation device and method
US20150112243A1 (en) * 2006-10-25 2015-04-23 Proteus Digital Health, Inc. Integrated Ingestible Event Marker System with Pharmaceutical Product
USD733102S1 (en) * 2014-03-18 2015-06-30 Doppler Labs, Inc. Ear bud
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
USD773641S1 (en) 2009-09-15 2016-12-06 Johnson & Johnson Consumer Inc. Oral dosage form
USD778842S1 (en) * 2013-08-08 2017-02-14 Omron Corporation Box cover for limit switch
USD780303S1 (en) * 2015-07-24 2017-02-28 Van M. Kassouni Ice melting tablet for melting ice and snow on walkways
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
USD793510S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
USD793513S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
USD793511S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
USD793512S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
USD801517S1 (en) * 2015-07-24 2017-10-31 Van M. Kassouni Ice melting tablet for melting ice and snow
USD816828S1 (en) * 2013-06-07 2018-05-01 Van M. Kassouni Ice melting tablet for melting ice and snow on walkways
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
USD832615S1 (en) * 2016-07-11 2018-11-06 City Global, Inc. Pillow
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10207093B2 (en) 2010-04-07 2019-02-19 Proteus Digital Health, Inc. Miniature ingestible device
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
USD864345S1 (en) * 2018-01-14 2019-10-22 Wei Yi Gun magnet mounting device
USD864166S1 (en) * 2018-06-13 2019-10-22 Dongguang Tingbei Electronic Technology Co., Ltd. Headset
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US10596209B2 (en) 2017-12-15 2020-03-24 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
USD895577S1 (en) * 2019-01-07 2020-09-08 Shure Acquisition Holdings, Inc. Earphone accessory
USD903230S1 (en) * 2019-08-08 2020-12-01 John Wade Evans Food patty
WO2020257722A2 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2023122193A2 (en) 2021-12-21 2023-06-29 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
US11819524B2 (en) 2018-09-05 2023-11-21 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
USD1020130S1 (en) * 2021-05-26 2024-03-26 Herddogg, Inc. Animal tag

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US109677A (en) * 1870-11-29 Improvement in confectionery for druggists
US701438A (en) * 1902-02-10 1902-06-03 Schieffelin And Company Compressed tablet.
US1267320A (en) * 1916-10-17 1918-05-21 Venola Company Confection.
US1516398A (en) * 1923-01-15 1924-11-18 Mcdowell Charles Gum dentifrice
US1855145A (en) * 1926-12-02 1932-04-19 Jones W Bartlett Edible article
US2312381A (en) * 1940-10-24 1943-03-02 Frank J Bickenheuser Medicinal tablet
US2809917A (en) * 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical tablets
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
US2957804A (en) * 1958-06-06 1960-10-25 Harlan R Shuyler Pesticide
US2966431A (en) * 1956-03-24 1960-12-27 Basf Ag Separation of filter material from carbon black
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US2991226A (en) * 1958-02-03 1961-07-04 Frosst & Co Charles E Long-acting wax-like talc pillage of penicillin

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US109677A (en) * 1870-11-29 Improvement in confectionery for druggists
US701438A (en) * 1902-02-10 1902-06-03 Schieffelin And Company Compressed tablet.
US1267320A (en) * 1916-10-17 1918-05-21 Venola Company Confection.
US1516398A (en) * 1923-01-15 1924-11-18 Mcdowell Charles Gum dentifrice
US1855145A (en) * 1926-12-02 1932-04-19 Jones W Bartlett Edible article
US2312381A (en) * 1940-10-24 1943-03-02 Frank J Bickenheuser Medicinal tablet
US2809917A (en) * 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical tablets
US2966431A (en) * 1956-03-24 1960-12-27 Basf Ag Separation of filter material from carbon black
US2991226A (en) * 1958-02-03 1961-07-04 Frosst & Co Charles E Long-acting wax-like talc pillage of penicillin
US2957804A (en) * 1958-06-06 1960-10-25 Harlan R Shuyler Pesticide
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets

Cited By (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125490A (en) * 1964-03-17 Tablet with contrasting indicia and method
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture
US3121044A (en) * 1960-10-06 1964-02-11 Beecham Res Lab Three-layer compressed penicillin tablet
US3125491A (en) * 1962-04-06 1964-03-17 Chew able hematinic vitamin tablet
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
FR2073278A1 (en) * 1969-12-17 1971-10-01 Sogeras Two-component tablets - having a distinctive pattern on one side
US3922338A (en) * 1973-07-12 1975-11-25 Choay Sa Tablets containing in their mass controlled-release micro-capsules and process for manufacture of said tablets
US4139589A (en) * 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4198390A (en) * 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
US4454108A (en) * 1981-09-04 1984-06-12 Chugai Seiyaku Kabushiki Kaisha Prolonged-action multiple-layer tablets
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
AU632602B2 (en) * 1989-08-02 1993-01-07 John David Arnold Method and preparation for reducing risk of myocardial infarction
US5213807A (en) * 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5849330A (en) * 1991-09-17 1998-12-15 Orion-Yhtyma Oy Controlled release pharmaceutical
US5599577A (en) * 1992-05-21 1997-02-04 Mcneil-Ppc, Inc. Simethicone containing pharmaceutical compositions
US5817340A (en) * 1992-12-01 1998-10-06 Mcneil-Ppc, Inc. Pharmaceutical compositions containing famotidine and aluminum hydroxide or magnesium hydroxide
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5759574A (en) * 1995-05-15 1998-06-02 Bothe; Steven T. Tel-tale-tablets
US20090088455A1 (en) * 1995-12-04 2009-04-02 Celgene Corporation Chronic, Bolus Adminstration Of D-Threo Methylphenidate
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6428770B1 (en) * 1997-12-03 2002-08-06 Kao Corporation Solid preparation for oral hygiene
USD420464S (en) * 1998-03-20 2000-02-08 Colgate-Palmolive Co. Detergent tablet
USRE41148E1 (en) 1998-10-21 2010-02-23 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20040219213A1 (en) * 1998-10-21 2004-11-04 Burnside Beth A. Oral pulsed dose drug delivery system
USRE42096E1 (en) 1998-10-21 2011-02-01 Shire LLC, USA Oral pulsed dose drug delivery system
KR101013272B1 (en) * 1998-12-04 2011-02-08 사노피-아벤티스 Controlled-release dosage forms comprising zolpidem or a salt thereof
USD430345S (en) * 1999-09-24 2000-08-29 Van Der Hagen John Two part circular soap article
US20060057201A1 (en) * 2002-07-25 2006-03-16 Bonney Stanley G Multicomponent pharmaceutical dosage form
US20060024365A1 (en) * 2002-08-05 2006-02-02 Navin Vaya Novel dosage form
US8263125B2 (en) * 2002-08-05 2012-09-11 Torrent Pharmaceuticals Limited Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040096499A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel dosage form
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US20040180089A1 (en) * 2002-12-26 2004-09-16 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US20070148229A1 (en) * 2003-04-24 2007-06-28 Jagotec Ag Tablet with coloured core
WO2004093850A1 (en) 2003-04-24 2004-11-04 Jagotec Ag Tablet with coloured core
JP2006524230A (en) * 2003-04-24 2006-10-26 ヤゴテック アーゲー Tablet with colored core
JP4908200B2 (en) * 2003-04-24 2012-04-04 ヤゴテック アーゲー Tablet with colored core
US10085771B2 (en) 2004-04-20 2018-10-02 Wm. Wrigley Jr. Company Breath freshening confectionery products and methods of making and using same
US20070166430A1 (en) * 2004-04-20 2007-07-19 Stawski Barbara Z Breath freshening confectionery products and methods of making and using same
US8557323B2 (en) 2004-04-20 2013-10-15 Wm. Wrigley Jr. Company Breath freshening confectionery products and methods of making and using same
US20090062336A1 (en) * 2004-04-26 2009-03-05 Celgene Corporation Methods of Diminishing Co-Abuse Potential
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
US20070054014A1 (en) * 2005-02-07 2007-03-08 Stawski Barbara Z Breath freshening confectionery products and methods of making and using same
US8431150B2 (en) 2005-02-07 2013-04-30 Wm. Wrigley Jr. Company Breath freshening confectionery products and methods of making and using same
US20060193909A1 (en) * 2005-02-07 2006-08-31 Stawski Barbara Z Breath freshening pressed tablets and methods of making and using same
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US11476952B2 (en) 2005-04-28 2022-10-18 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US10610128B2 (en) 2005-04-28 2020-04-07 Proteus Digital Health, Inc. Pharma-informatics system
US10542909B2 (en) 2005-04-28 2020-01-28 Proteus Digital Health, Inc. Communication system with partial power source
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
US9681842B2 (en) 2005-04-28 2017-06-20 Proteus Digital Health, Inc. Pharma-informatics system
US10517507B2 (en) 2005-04-28 2019-12-31 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
WO2007043061A1 (en) * 2005-10-11 2007-04-19 Ipca Laboratories Ltd. Anti-malarial combination and methods of formulation
US20070166380A1 (en) * 2005-11-18 2007-07-19 Frans Van Dalen Zolpidem tablets
US8148393B2 (en) 2005-11-18 2012-04-03 Synthon Bv Zolpidem tablets
US8883217B2 (en) 2006-03-16 2014-11-11 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US9675704B2 (en) 2006-03-16 2017-06-13 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US10172958B2 (en) 2006-03-16 2019-01-08 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US9198864B2 (en) 2006-03-16 2015-12-01 Tris Pharma, Inc Modified release formulations containing drug-ion exchange resin complexes
US8747902B2 (en) 2006-03-16 2014-06-10 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US9549989B2 (en) 2006-03-16 2017-01-24 Tris Pharma, Inc Modified release formulations containing drug-ion exchange resin complexes
US10933143B2 (en) 2006-03-16 2021-03-02 Tris Pharma, Inc Modified release formulations containing drug-ion exchange resin complexes
US9522191B2 (en) 2006-03-16 2016-12-20 Tris Pharma, Inc. Modified release formulations containing drug—ion exchange resin complexes
US10086087B2 (en) 2006-03-16 2018-10-02 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US10668163B2 (en) 2006-03-16 2020-06-02 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US9675703B2 (en) 2006-03-16 2017-06-13 Tris Pharma, Inc Modified release formulations containing drug - ion exchange resin complexes
US9173857B2 (en) 2006-05-12 2015-11-03 Shire Llc Controlled dose drug delivery system
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US20070264323A1 (en) * 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system
US7976872B2 (en) 2006-07-24 2011-07-12 L. Perrigo Company Method for distributing a pharmaceutically active compound in an excipient
US20080020047A1 (en) * 2006-07-24 2008-01-24 Alexander Thomas A Method for distributing a pharmaceutically active compound in an excipient
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US9504699B2 (en) 2006-08-03 2016-11-29 Hznp Limited Delayed-release glucocorticoid treatment of rheumatoid disease
US9402813B2 (en) 2006-10-09 2016-08-02 Locl Pharma, Inc. Pharmaceutical compositions
US9393207B2 (en) 2006-10-09 2016-07-19 Locl Pharma, Inc. Pharmaceutical compositions
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US20100143469A1 (en) * 2006-10-09 2010-06-10 Paul Bosse Pharmaceutical compositions
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
US9399022B2 (en) 2006-10-09 2016-07-26 Locl Pharma, Inc. Pharmaceutical compositions
US9427407B2 (en) 2006-10-09 2016-08-30 Locl Pharma, Inc. Pharmaceutical compositions
US20150112243A1 (en) * 2006-10-25 2015-04-23 Proteus Digital Health, Inc. Integrated Ingestible Event Marker System with Pharmaceutical Product
US20090087483A1 (en) * 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US20090232886A1 (en) * 2007-09-27 2009-09-17 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US9539400B2 (en) 2007-10-09 2017-01-10 Microdose Therapeutx, Inc. Inhalation device
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
US9132246B2 (en) 2007-10-09 2015-09-15 Microdose Therapeutx, Inc. Inhalation device
US20090090361A1 (en) * 2007-10-09 2009-04-09 Anand Gumaste Inhalation device
US20090108492A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Method and apparatus for manufacturing filled linkers
US20090110721A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Paneled capsule shells for release of pharmaceutical compositions
US8454992B2 (en) 2007-10-15 2013-06-04 Capsugel Belgium Nv Paneled capsule shells for release of pharmaceutical compositions
US8293159B2 (en) 2007-10-15 2012-10-23 Capsugel Belgium Method and apparatus for manufacturing filled linkers
US20090110723A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
US9198867B2 (en) 2008-01-09 2015-12-01 Charleston Laboratories, Inc. Pharmaceutical compositions
US10064856B2 (en) 2008-01-09 2018-09-04 Local Pharma, Inc. Pharmaceutical compositions
US9855264B2 (en) 2008-01-09 2018-01-02 Locl Pharma, Inc. Pharmaceutical compositions
US9789104B2 (en) 2008-01-09 2017-10-17 Locl Pharma, Inc. Pharmaceutical compositions
US9789105B2 (en) 2008-01-09 2017-10-17 Locl Pharma, Inc. Pharmaceutical compositions
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US9498444B2 (en) 2008-01-09 2016-11-22 Locl Pharma, Inc. Pharmaceutical compositions
US9775837B2 (en) 2008-01-09 2017-10-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US9226901B2 (en) 2008-01-09 2016-01-05 Locl Pharma, Inc. Pharmaceutical compositions
US9387177B2 (en) 2008-01-09 2016-07-12 Locl Pharma, Inc. Pharmaceutical compositions
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US20100196427A1 (en) * 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9808481B2 (en) 2009-02-24 2017-11-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9579340B2 (en) 2009-02-24 2017-02-28 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9592248B2 (en) 2009-02-24 2017-03-14 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9775860B2 (en) 2009-02-24 2017-10-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US8728522B2 (en) 2009-07-08 2014-05-20 Charleston Laboratories, Inc. Pharmaceutical compositions for treating or preventing pain
US9526704B2 (en) 2009-07-08 2016-12-27 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain
US10016368B2 (en) 2009-07-08 2018-07-10 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain
US9433625B2 (en) 2009-07-08 2016-09-06 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain
US10532030B2 (en) 2009-07-08 2020-01-14 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain
USD773641S1 (en) 2009-09-15 2016-12-06 Johnson & Johnson Consumer Inc. Oral dosage form
US9974909B2 (en) 2010-01-05 2018-05-22 Microdose Therapeutx, Inc. Inhalation device and method
US8991390B2 (en) 2010-01-05 2015-03-31 Microdose Therapeutx, Inc. Inhalation device and method
US10434267B2 (en) 2010-01-05 2019-10-08 Microdose Therapeutx, Inc. Inhalation device and method
US10207093B2 (en) 2010-04-07 2019-02-19 Proteus Digital Health, Inc. Miniature ingestible device
US11173290B2 (en) 2010-04-07 2021-11-16 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
USD666377S1 (en) * 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
USD666376S1 (en) * 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
USD697510S1 (en) * 2011-03-23 2014-01-14 Brother Industries, Ltd. Scanner with projector
US9265737B2 (en) 2011-06-28 2016-02-23 Neos Therapeutics, Lp Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
US9017731B2 (en) 2011-06-28 2015-04-28 Neos Therapeutics, Lp Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
US9839619B2 (en) 2011-06-28 2017-12-12 Neos Therapeutics, Lp Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles
US8709491B2 (en) 2011-06-28 2014-04-29 NEOS Terapeutics, LP Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
US9089496B2 (en) 2011-06-28 2015-07-28 Neos Therapeutics, Lp Compositions comprising methylphenidate complexed with ion-exchange resin particles
US9072680B2 (en) 2011-06-28 2015-07-07 Neos Therapeutics, Llp Compositions comprising methylphenidate complexed with ion-exchange resin particles
US11229378B2 (en) 2011-07-11 2022-01-25 Otsuka Pharmaceutical Co., Ltd. Communication system with enhanced partial power source and method of manufacturing same
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
USD677438S1 (en) * 2011-12-13 2013-03-05 Sunbeam Products, Inc. Bark control device housing
US20130295174A1 (en) * 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Tablet comprising a first and second region
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
USD908202S1 (en) 2013-06-07 2021-01-19 Kassouni Manufacturing, Inc. Ice melting tablet for melting ice and snow on walkways
USD816828S1 (en) * 2013-06-07 2018-05-01 Van M. Kassouni Ice melting tablet for melting ice and snow on walkways
USD778842S1 (en) * 2013-08-08 2017-02-14 Omron Corporation Box cover for limit switch
USD859322S1 (en) 2013-08-08 2019-09-10 Omron Corporation Box cover for limit switch
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10421658B2 (en) 2013-08-30 2019-09-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
USD714787S1 (en) * 2013-09-12 2014-10-07 Hiku Labs, Inc. Handheld device
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11950615B2 (en) 2014-01-21 2024-04-09 Otsuka Pharmaceutical Co., Ltd. Masticable ingestible product and communication system therefor
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
USD733102S1 (en) * 2014-03-18 2015-06-30 Doppler Labs, Inc. Ear bud
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
USD870262S1 (en) * 2015-07-24 2019-12-17 Van M. Kassouni Ice melting tablet for melting ice and snow
USD801517S1 (en) * 2015-07-24 2017-10-31 Van M. Kassouni Ice melting tablet for melting ice and snow
USD780303S1 (en) * 2015-07-24 2017-02-28 Van M. Kassouni Ice melting tablet for melting ice and snow on walkways
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US10772840B2 (en) 2016-03-04 2020-09-15 Charleston Laboratories, Inc. Sumatriptan promethazine pharmaceutical compositions
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
USD793510S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
USD793513S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
USD793511S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
USD793512S1 (en) * 2016-06-03 2017-08-01 Comfort Research, Llc Water float
USD832615S1 (en) * 2016-07-11 2018-11-06 City Global, Inc. Pillow
US10797758B2 (en) 2016-07-22 2020-10-06 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11793419B2 (en) 2016-10-26 2023-10-24 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US10596209B2 (en) 2017-12-15 2020-03-24 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
US11793841B2 (en) 2017-12-15 2023-10-24 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
USD864345S1 (en) * 2018-01-14 2019-10-22 Wei Yi Gun magnet mounting device
USD864166S1 (en) * 2018-06-13 2019-10-22 Dongguang Tingbei Electronic Technology Co., Ltd. Headset
US11819524B2 (en) 2018-09-05 2023-11-21 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
USD895577S1 (en) * 2019-01-07 2020-09-08 Shure Acquisition Holdings, Inc. Earphone accessory
WO2020257722A2 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
USD903230S1 (en) * 2019-08-08 2020-12-01 John Wade Evans Food patty
USD1020130S1 (en) * 2021-05-26 2024-03-26 Herddogg, Inc. Animal tag
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US11938158B2 (en) 2021-11-22 2024-03-26 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2023122193A2 (en) 2021-12-21 2023-06-29 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Similar Documents

Publication Publication Date Title
US3048526A (en) Medicinal tablet
US3096248A (en) Method of making an encapsulated tablet
US3922338A (en) Tablets containing in their mass controlled-release micro-capsules and process for manufacture of said tablets
US3146169A (en) Pharmaceutical formulations and their manufacture
US3080294A (en) Sustained release type of pharmaceutical vehicles
US3336200A (en) Tablet structure
US3131123A (en) Enteric tablets and manufacture thereof
US3344029A (en) Sustained release composition
US5824338A (en) Caplet and gelatin covering therefor
US5415868A (en) Caplets with gelatin cover and process for making same
US2887438A (en) Prolonged action tablets
US6258381B1 (en) Tablet and process for making the same
KR0156841B1 (en) Apparatus for film-enrobed unitary core medicament
RU96107115A (en) INTEGRATED UNIT DOSAGE FORM 1 AS TABLET
RU96107106A (en) NEW GRANULES FOR REGULATED RELEASE AND PHARMACEUTICAL DRUGS CONTAINING SUCH GRANULES
UA41946C2 (en) Oral pharmaceutical tablet compound dosage form, method for manufacture, blister package, and method for inhibiting acid secretion in stomach and/or treating gastrointestinal inflammatory diseases
CA2348090A1 (en) Oral pulsed dose drug delivery system
US6113945A (en) Multi-colored medicament
GB1310594A (en) Antidepressant compositions and dosage units
US2536168A (en) Amphetamine chewing gum
KR20080034517A (en) Preparation with accurate dose-dividing function
US2809917A (en) Sustained release pharmaceutical tablets
US6083533A (en) Layered tablet for the controlled release of active substances
US2921001A (en) Multi-layered pill or tablet with indicating lamination
GB1022171A (en) Prolonged release oral pharmaceutical tablets and their manufacture